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ABSTRACT

Currently there are three platinum anticancer drugs on the market: cisplatin,
oxaliplatin, and carboplatin. These compounds have variable leaving ligands, which are
the locations on compounds that will be replaced by biological targets (DNA and
protein). The purpose of this research is testing platinum compounds that have a
nonleaving ethylenediamine or diaminocyclohexane ligand, similar to the nonleaving
ligands found in cisplatin and oxaliplatin, and variable leaving ligands. Three compounds
were tested including oxaliplatin, ethylenediamine(oxalato)platinum(II) (Pt(en)(ox)), and
dichloro(ethylenediamine)platinum(II) (Pt(en)Cl2). MTT assays were performed on
cancer cells treated with the platinum compounds for twenty-four hours. In MTT assays,
the living cells can reduce a tetrazolium salt to a purple formazan that is quantified to
determine percent cell survival. The testicular cancer cell line NTERA-2 showed a higher
sensitivity to Pt(en)(ox) than the colorectal cancer cell line HT-29. The NTERA-2 cells
were 2.5 times more sensitive to Pt(en)(ox) than to the therapeutic standard oxaliplatin.
Also, the HT-29 and NTERA-2 cancer cell lines had similar toxicities to oxaliplatin.
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CHAPTER 1

INTRODUCTION

Michele Peyrone first synthesized cis-diamminedichloroplatinum(II), which is
now known as cisplatin, in 1844 [1]. Cisplatin would later become a widely used cancer
treatment and lead to the development of a new family of anticancer treatments. The
Rosenberg laboratory was the first to discover that platinum-containing compounds
interfered with cell growth. In the 1960s, the Rosenberg laboratory unintentionally
discovered the anticancer effects of platinum after observing a halt in cell division of
Escherichia coli bacteria when placed into solution with platinum electrodes [2].
Originally it was thought that the halt in cell division was due to the electric field caused
by the electrodes, but it was later discovered that the platinum in the electrodes was
responsible for the halt in cell division. Further studies with a sarcoma mouse model
showed that the platinum compound cisplatin had the ability to kill cancer cells and
shrink tumors [2]. However, there was concern over the toxic effects of heavy metals on
the body. It was later shown that in low doses the mice still showed tumor shrinkage and
less toxic effects [2]. Cisplatin was later approved by the Food and Drug Association in
1978 after human clinical trials had been performed, and has been effective in treating
testicular and ovarian cancers.
The cytotoxicity of cisplatin is due to its binding with deoxyribonucleic
1

acid (DNA) and the formation of DNA intrastrand cross-linkages, which interfere with
cell division and lead to apoptosis. These platinum containing compounds are made up of
two types of ligands referred to as the leaving and nonleaving ligands. The leaving
ligands are the species in a compound that will be replaced by the DNA or protein target,
whereas the nonleaving ligand will stay bound to the DNA or protein target. Cisplatin has
chloride leaving ligands and amino group (NH3) nonleaving ligands, which are shown in
Figure 1.1.

Figure 1.1. The structure of cisplatin with the chloride leaving ligands and amino group
nonleaving ligands bound to platinum.

Platinum compounds are thought to go across cell membranes through passive
diffusion and carrier-mediated active transport [3]. One form of carrier-mediated active
transport is the human copper influx transporter CTR1, which is a transmembrane
homotrimer that forms a pore in cell membranes. The CTR1 pore has cysteine,
methionine, and histidine amino-acid-rich domains through which the copper can then
pass [4]. It is thought that cisplatin, carboplatin, and oxaliplatin can also use the CTR1
2

transporter to enter cells since the platinum compounds are attracted to the nucleophilic
cysteine and methionine sulfur atoms, which are found in the pores formed by the CTR1
transporter. This idea is supported by experiments on mammalian cells without the CTR1
transporter that showed decreased uptake of the platinum compounds [4]. Also, the CTR1
transporter being used as a way for platinum compounds to enter cells is supported by the
Hard-Soft Acid-Base Theory, which says that hard acids react more strongly with hard
bases and soft acids react more strongly with soft bases. Platinum is considered a soft
acid because of its high polarizability and large atomic radius, and sulfur is a soft base
because of its large atomic radius and high polarizability. Since the methionine and
cysteine residues in the pore formed by the CTR1 transporter have sulfur atoms, the Hard
Soft Acid Base theory suggests that the platinum compounds would be likely to interact
with the amino acid residues in the pore. Therefore, it is thought that CTR1 transporter is
one process allowing platinum compounds to enter cells.
Cisplatin is able to travel throughout the bloodstream in its regular form shown in
Figure 1.1. However, since the chloride ion concentration is low in the cytosol, water can
replace the chloride leaving ligands. Therefore, the activated form of cisplatin
[Pt(NH3)2(H2O)2]2+ can act as an electrophile and bind to DNA bases forming platinumDNA adducts [5]. Cisplatin predominantly binds to the N7 atom of the guanine base in
DNA because it is a good nucleophile, which causes primarily 1,2-intrastrand
crosslinking of DNA [6]. Secondarily cisplatin can also bind to the adenine nitrogenous
base in DNA or to proteins, which can cause different crosslinking types. The platinumDNA adducts formed inhibit transcription of the cancer cell’s DNA and cause apoptosis,
3

which is programmed cell death [8]. The potential crosslinks formed are shown in Figure
1.2 [7].

Figure 1.2. Figure showing the potential intrastrand crosslinking of cisplatin with DNA
or proteins [7].

The discovery of cisplatin led to further studies into platinum-containing
compounds and the Food and Drug Association approval of a cisplatin analog known as
carboplatin or cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) in 1989.
Carboplatin differs from cisplatin because it has a different leaving ligand, which is
cyclobutane-1,1-dicarboxylic acid (CBDCA) instead of the chloride leaving ligands
found in cisplatin. The structure of carboplatin is shown in Figure 1.3. The mechanism of
4

action of carboplatin is similar to cisplatin and involves the formation of platinum-DNA
adducts leading to apoptosis.

Figure 1.3. Structure of carboplatin with the same nonleaving ligands (NH3) as cisplatin
and a CBDCA leaving ligand.

In 2002, another platinum-containing anticancer drug, oxaliplatin or (R,R)-1,2diaminocyclohexane(oxalato)platinum(II), was also approved by the Food and Drug
Association. Oxaliplatin has been most effective in treating colorectal cancer. Oxaliplatin
is different from cisplatin in both its leaving ligand, which is oxalate, and its nonleaving
ligand, which is diaminocyclohexane. Oxaliplatin has been shown to have a similar
mechanism of action as cisplatin for killing cancer cells, and oxaliplatin forms similar
platinum-DNA adducts. The structure of oxaliplatin is shown in Figure 1.4.

5

Figure 1.4. Structure of oxaliplatin with a diaminocyclohexane nonleaving ligand and an
oxalate leaving ligand.

While all three FDA approved platinum-containing compounds have been shown
to be effective in killing cancer cells, they also each have toxic side effects. These side
effects include nephrotoxicity, neurotoxicity, and ototoxicity. Nephrotoxicity refers to
damage to the kidneys due to toxic substances. Cisplatin has been shown to cause acute
kidney injury, and the nephrotoxicity increases with a higher frequency of treatments
with cisplatin [8]. Oxaliplatin has been shown to produce transient neurotoxicity in
patients, which is damage to the nervous system due to toxic substances [9]. One
symptom of neurotoxicity reported with oxaliplatin is peripheral neuropathy including
cold dysesthesia, which is when parts of the body are extremely sensitive to cold
temperatures [9]. Ototoxicity is damage to the ears due to toxic substances, and it has
been shown to affect patients treated with oxaliplatin for testicular cancer by impairing
6

their hearing [10]. Therefore, further study into platinum-containing anticancer
compounds is important to help develop more efficient and safer cancer treatments.
One important avenue of study is the toxicity effects of changing the leaving or
nonleaving ligands of the platinum compounds. Since the leaving ligand becomes
activated in the cytosol of the cell and is able to attack a DNA or protein target, changing
the leaving ligand could potentially impact the ability of the compound to kill the cancer
cells. Also, the nonleaving ligand could impact the ability of the compound to kill cancer
cells since its size, charge, or stereochemistry could affect the binding of the compound
to its biological target. Therefore, this research compares the toxicity of compounds with
varying ligands to observe any changes in toxicity due to a particular ligand or
differences in the toxicity of platinum compounds when used on different cancer cell
lines.

7

CHAPTER 2

METHODOLOGY

Three platinum compounds were used as treatments on cancer cells. The toxicity
of the platinum compounds was then determined by performing cell survival assays on
the cancer cells. The three compounds tested were dichloro(ethylenediamine)platinum(II)
referred to as Pt(en)Cl2, ethylenediamine(oxalato)platinum(II) referred to as Pt(en)(ox),
and oxaliplatin. Pt(en)Cl2 has the same chloride leaving ligands as cisplatin, but a
different nonleaving ligand. The nonleaving ligand in Pt(en)Cl2 is an ethylenediamine
ligand. Pt(en)(ox) has the same nonleaving ligand as Pt(en)Cl2, and the leaving ligand in
Pt(en)(ox) is the same oxalate leaving ligand that is found in oxaliplatin. Oxaliplatin was
tested as well and it has an oxalate leaving ligand and a diaminocyclohexane nonleaving
ligand.
Pt(en)Cl2 was bought commercially from Sigma-Aldrich. The other two platinum
compounds were synthesized as detailed below and their molecular structures were
determined using a JEOL Eclipse 500 MHz NMR Spectrometer. The synthesis of silver
oxalate is also described because it was used in the synthesis of both oxaliplatin and
ethylenediamine(oxalato)platinum(II). The structures of Pt(en)Cl2, Pt(en)(ox), and
oxaliplatin are shown in Figure 2.1.
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Figure 2.1. Structures of the platinum compounds tested including Pt(en)Cl2, Pt(en)(ox),
and oxaliplatin.

Synthesis of Platinum Compounds

Silver Oxalate:
Silver oxalate was synthesized by combining 500 mg (2.94 mmol) of silver
nitrate, 150 mg (1.67 mmol) of oxalic acid, and 10 ml of deionized water in an amber
vial. The mixture was stirred for 24 hours and a white precipitate formed. The solution
was vacuum filtered, and ethanol was used to rinse the amber vial. The dried precipitate
was collected, and the procedure yielded 319.1 mg of silver oxalate. The silver oxalate
was stored in the dark.

9

Oxaliplatin:
First two separate solutions were made in small beakers and stirred for 5 minutes.
The first solution consisted of 232 mg (0.559 mmol) of potassium tetrachloroplatinate(II)
and 5 ml of deionized water, and the second solution consisted of 64 mg (0.560 mmol) of
(R,R)-1,2-diaminocyclohexane and 5 ml of methanol. Next, the second solution was
added dropwise to the first. The resulting solution was stirred for 24 hours and a color
change occurred from red to yellow. The yellow precipitate was separated from solution
using vacuum filtration. The precipitate was dried and 127.9 mg was the yield.
59.5 mg (0.157 mmol) of the yellow precipitate was combined with 47.4 mg
(0.156 mmol) of silver oxalate and 35 ml of deionized water. The solution was stirred for
48 hours and then syringe filtered. A rotary evaporator was used to dehydrate the product.
The synthesis of oxaliplatin yielded 37.2 mg.

Ethylenediamine(oxalato)platinum(II) or Pt(en)(ox):
Pt(en)(ox) was synthesized by combining 65.2 mg (0.200 mmol) of Pt(en)Cl2 with
67 mg (0.221 mmol) of silver oxalate and 40 ml of deionized water. The solution was
stirred for 24 hours in an amber vial. The white solution was then syringe filtered, and a
rotary evaporator was used to dehydrate the product. The synthesis of Pt(en)(ox) yielded
80.2 mg.
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Platinum Compound Toxicity Testing in Cancer Cells

Three cell lines were cultured for experiments including the colorectal cancer cell
lines HT-29 and Caco-2 and the testicular cancer cell line NTERA-2. The testing was
done on colorectal and testicular cancer cells since cisplatin and oxaliplatin are known to
be effective at killing these cell types. The cells were purchased from the American Type
Culture Collection (ATCC). The Caco-2 and HT-29 cell lines were derived from human
epithelial cells of the colon from a person with colorectal adenocarcinoma [11]. The
NTERA-2 cell line was derived from human epithelial cells of the testes from a person
with malignant pluripotent embryonal carcinoma [11]. The Caco-2 and HT-29 cells were
grown in Eagle’s Minimum Essential Medium (EMEM) with the addition of 10% fetal
bovine serum, L-glutamine, and Penicillin-Streptomycin. The NTera-2 cells were grown
in Dulbecco’s Modification of Eagle’s Medium (DMEM) with the addition of 10% fetal
bovine serum, L-glutamine, and Penicillin-Streptomycin. The mammalian cells were
cultured in an aseptic environment using standard cell culturing protocols and were stored
in an incubator at 37℃ and 5% carbon dioxide.
To maintain the growth of the cells, the cells were subcultured when they had
grown and divided until it was visibly clear that ~75% of the plate was covered with
cells. Subculturing the cells consisted of using phosphate buffered solution to rinse the
cells, followed by incubating the cells with 1 ml of trypsin per 10 cm plate. Trypsin is a
protease that hydrolyzes proteins at the serine residues of the easily accessible cell
adhesion molecules. Therefore, adding trypsin to the cells causes the cells to loosen from
11

the tissue culture plate and allow the cells to be easily divided. In order to stop the
function of the trypsin, 4 ml of media was added to the plate. The media has 10% fetal
bovine serum, which consists of a large quantity of proteins. Therefore, adding the media
will stop the trypsin from digesting the cell proteins because the fetal bovine serum will
allow for an overabundance of proteins for the trypsin to digest instead of cell proteins.
The cells were then counted using a Neubauer hemocytometer, which is an instrument
used to count cells manually with a microscope. The hemocytometer used was a small
glass instrument that held 10 𝜇l of cells in media. The Neubauer hemocytometer has a
defined length (1.0 mm), width (1.0 mm), and height (0.1 mm). Also, it has a grid on it
that allows for the number of cells in a portion of the grid to be counted visually with the
help of a microscope. Based on the number of cells counted in a portion of the grid and
the known volume of the hemocytometer, the cell density can be determined. The cells
were grown on 10 cm plates with a cell density of 500,000 cells/ml.
For experimental testing, the cells were counted using a hemocytometer and
500,000 cells/ml were plated onto a Greiner Bio-One 24 well cell culture plate. The cells
were then incubated for 48 hours to allow the cells to adhere to the plate and start
growing. The platinum compounds were diluted with media to the concentrations shown
in the results section. Since each plate had 24 wells, the first three wells were control
wells that had untreated cells with fresh media added so that they could continue growing
in the wells. The other 21 wells were in groups where each platinum compound
concentration was done in triplicate. For experimental testing, the cells were treated with
300 𝜇l of the platinum compounds per well. The treatments were left on the cells for 24
12

hours. Then the platinum compounds were removed using a vacuum, and the MTT assays
were performed.
The MTT assay included adding the MTT reagent, which is 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide salt, to the cells. The MTT
reagent can be reduced by the enzymes in the mitochondria of living cells to a purple
formazan. The reduction reaction and color change can only occur in living cells.
Therefore, the color change can be quantified and used to determine percent cell survival.
The experimental procedure for the MTT assays included treating each well of cells with
300 𝜇l of 0.5% MTT salt in DMEM or MEM. The MTT salt and media solution were left
on the cells for 3 hours and then removed. Next, a solution was made consisting of 25 𝜇l
of Sorenson’s Buffer (0.1 M glycine, 0.1 M sodium chloride, and pH adjusted to 10.5
with sodium hydroxide) for every 200 𝜇l of dimethyl sulfoxide (DMSO). 200 𝜇l of the
Sorenson’s Buffer and DMSO solution was added to each well. The Sorenson’s Buffer is
a salt mixture that causes the cells to lyse, which releases the salts within the cells. The
release of the salts inside the cells allows for the color change to be visible in the wells
since the MTT salt (yellow) in dead cells or formazan (purple) in previously living cells
is released.
The color change was quantified by measuring absorbance values at a wavelength
of 550 nm using a Synergy H1 plate reader. Then calculations were performed to
determine percent cell survival. The plate reader gave the absorbance value of each well.
Since each concentration of platinum compound exposure was done in triplicate, the
absorbance values for the three replicate wells were averaged. The absorbance values of
13

the three control wells were also averaged. The average absorbance value for each
platinum compound concentration was then normalized to the three control wells’
average absorbance. The proportion of absorbance values was then converted to a
percentage, which is the percent cell survival. When plating the cells the density was kept
low enough to allow the cells to continue growing normally throughout the experiment.
Therefore, the only cell death observed would come from treatment with a platinum
compound and not from the density of cells being too high, which could inhibit cell
growth.

14

CHAPTER 3

RESULTS

The MTT assays performed on the Caco-2, HT-29, and NTERA-2 cell lines
allowed for the calculation of percent cell survival by comparing the absorbance reading
of each platinum exposure to the untreated cells. Once the percent cell survival values
from the MTT assays was calculated, it was graphed as a function of the concentration of
the platinum compound treatment. In order to compare the toxicity of each compound
used to treat the three different cell lines, the IC-50 values were determined. The IC-50
value is the inhibitory concentration where the activity of a biological process has
decreased by 50%. For this research, the IC-50 values show the concentration of platinum
compound needed to inhibit 50% of the activity of the mitochondrial enzymes, which
convert the yellow MTT salt to a purple formazan. Therefore, a lower IC-50 value
corresponds to a higher toxicity because a lower concentration of that compound can
decrease the mitochondrial enzyme activity of the cancer cells by 50%. On the other
hand, a higher IC-50 value corresponds to a lower toxicity. The error bars on all of the
graphs correspond to the standard error.
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Figure 3.1 Graph shows the results of the MTT assays on the Caco-2 colorectal cancer
cells treated with Pt(en)Cl2. The IC-50 value for Pt(en)Cl2 is 50 𝜇M.
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Figure 3.2 Graph shows the results of the MTT assays on the HT-29 colorectal cancer
cells treated with Pt(en)(ox). The IC-50 value for Pt(en)(ox) is 25 𝜇M.
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Figure 3.3. Graph shows the results of the MTT assay on the HT-29 colorectal cancer
cells treated with oxaliplatin. The IC-50 value for oxaliplatin is 30 𝜇M.
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The graphs in Figures 3.1, 3.2, and 3.3 all show the results of MTT assays
performed on colorectal cancer cells. Pt(en)ox had the lowest IC-50 value, which
corresponds to the highest toxicity. Also, the IC-50 value was highest for Pt(en)Cl2,
which corresponds to the lowest toxicity. The IC-50 values for oxaliplatin and Pt(en)(ox)
were very similar at 30 𝜇M and 25 𝜇M, respectively. Both Pt(en)(ox) and oxaliplatin
have the same oxalate leaving ligand but differ in their nonleaving ligand.
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Figure 3.4. This graph shows the results of the MTT assays on the NTERA-2 testicular
cancer cells treated with Pt(en)Cl2. The IC-50 value for Pt(en)Cl2 is estimated to be
between 1.5-50 μM. However, a more specific IC-50 value could not be determined from
the concentrations of Pt(en)Cl2 tested.
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Figure 3.5. Graph shows the data from the MTT assay on NTERA-2 testicular cancer
cells treated with Pt(en)(ox). The IC-50 value for Pt(en)(ox) is 14 𝜇M.
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Figure 3.6. Graph shows the data from the MTT assay on NTERA-2 testicular cancer
cells treated with oxaliplatin. The IC-50 value for oxaliplatin is 35 𝜇M.
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The graphs shown in Figures 3.4, 3.5, and 3.6 show the results of the MTT assays
performed on NTERA-2 testicular cancer cells. Pt(en)(ox) had the lowest IC-50 value
(14 𝜇M), which corresponds to a higher toxicity. Comparing between the different cell
lines, Pt(en)(ox) had the lowest IC-50 value in both the testicular and colorectal cancer
cells. The Pt(en)(ox) IC-50 value was 25 𝜇M in the HT-29 cells and 14 𝜇M in the
NTERA-2 cells. Interestingly, the oxaliplatin IC-50 values were similar between the
NTERA-2 cells, which had an IC-50 value of 35 𝜇M, and the HT-29 cells, which had an
IC-50 value of 30 𝜇M.
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CHAPTER 4

DISCUSSION

Following the analysis of the MTT assay data, the different leaving and
nonleaving ligands have been shown to affect the toxicity of the platinum containing
compounds on colorectal and testicular cancer cells. The three platinum compounds
tested showed differing IC-50 values, which corresponds to different toxicity levels,
between the different cancer cell lines. Therefore, the different cancer cell types had
different sensitivity to the platinum compounds. A summary of the IC-50 values sorted
by leaving ligand is shown in Table 4.1.

Platinum Compound

Leaving Ligand

Cell Line

IC-50 Value (𝜇M)

Pt(en)(ox)

Oxalate

HT-29

25

Pt(en)(ox)

Oxalate

NTERA-2

14

Oxaliplatin

Oxalate

HT-29

30

Oxaliplatin

Oxalate

NTERA-2

35

Pt(en)Cl2

Chloride

Caco-2

50

Pt(en)Cl2

Chloride

NTERA-2

~1.5-50

Table 4.1 This is a summary chart of the IC-50 values sorted by leaving ligand.
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For the HT-29 colorectal cancer cell line the Pt(en)(ox), which had an IC-50 value
of 25 𝜇M, had the lowest IC-50 value. The lower the IC-50 value the lower the
concentration of the compound needed to kill 50% of the cancer cells, which corresponds
to a higher toxicity. As seen in Figure 4.1, the HT-29 colorectal cancer cells Pt(en)(ox)
had a similar IC-50 value to oxaliplatin, which had an IC-50 value of 30 𝜇M. Pt(en)(ox)
and oxaliplatin have the same leaving oxalate ligand, which suggests that in the HT-29
cells the oxalate leaving ligand affects the toxicity of the platinum compound.
For the testicular cell line NTERA-2 it was determined that Pt(en)(ox) also had
the lowest IC-50 value, which corresponds to a higher toxicity. However, in the NTERA2 cells the Pt(en)(ox) and oxaliplatin IC-50 values were significantly different. The
Pt(en)(ox) IC-50 value in the NTERA-2 cells was 14 𝜇M, whereas the IC-50 value for
oxaliplatin in the NTERA-2 cancer cells was 35 𝜇M. Therefore, the NTERA-2 cancer
cells were 2.5 times more sensitive to Pt(en)(ox) as to oxaliplatin.
Oxaliplatin has been shown to have an IC-50 value of 1.81±1.15 𝜇M in HT-29
cells treated with oxaliplatin for 72 hours, and an IC-50 value of 1.12±0.08 𝜇M in
NTERA-2 cells treated with oxaliplatin for 72 hours [12]. The experimental IC-50 values
determined from the MTT assays are higher because the cells were treated for a shorter
period of time. The ability of the platinum compounds to kill cancer cells is thought to
depend on the amount of the platinum compound that accumulates in the cell, which
causes intrastrand crosslinking with DNA. Therefore, for the 24 hour treatments the IC50 values could have been higher because less of the platinum compounds were able to
accumulate in the cancer cells and cause apoptosis during the narrow time window.
22

Also, the Caco-2 colorectal cancer cells treated with Pt(en)Cl2 had an IC-50 value
of 50 𝜇M, which is higher than both the Pt(en)(ox) and oxaliplatin IC-50 values in the
HT-29 colorectal cancer cell line. Therefore, the Caco-2 cancer cells had a higher
sensitivity to the Pt(en)Cl2 than the HT-29 cancer cells had to Pt(en)(ox) or oxaliplatin.
For the NTERA-2 cells treated with Pt(en)Cl2 the specific IC-50 value was not
determined based on the data collected. At a 50 𝜇M concentration of Pt(en)Cl2 the
percent cell survival was 30%. However, the NTERA-2 cancer cells treated with
oxaliplatin never dropped below 40% cell survival even at the 60 𝜇M concentration.
Therefore, the NTERA-2 cancer cells seem to be more sensitive to Pt(en)Cl2. Pt(en)Cl2
has the same chloride leaving ligands as cisplatin, and in the literature IC-50 values on
NTERA-2 cells treated for 72 hours the same trend is seen between cisplatin and
oxaliplatin IC-50 values. For the literature IC-50 values of NTERA-2 cancer cells treated
for 72 hours, cisplatin had an IC-50 of 0.14±0.03𝜇M and oxaliplatin had an IC-50 value
of 1.12±0.08 𝜇M [12]. Therefore, the literature IC-50 values show NTERA-2 cancer
cells being more sensitive to cisplatin than to oxaliplatin, and the experimental results
show the NTERA-2 cancer cells showing the same trend of being more sensitive to the
compound with the same chloride leaving ligands as cisplatin.
Overall, it was shown that the toxicity of the platinum compounds differed
between cell lines and that the compound with the highest toxicity in both cancer cell
types was Pt(en)(ox). Pt(en)(ox) had a lower IC-50 value and higher toxicity in both cell
lines than the therapeutic standard drug treatment, which is oxaliplatin. The NTERA-2
cells were 2.5 times more sensitive to Pt(en)(ox) than to oxaliplatin. The literature IC-50
23

values were lower after the cancer cells had been treated for 72 hours than the
experimentally determined IC-50 values, which were determined after treating the cancer
cells for 24 hours. This supports the belief that cancer cell death is dependent upon the
amount of the platinum compound that accumulate in the cancer cells, which leads to
intrastrand crosslinking with DNA and apoptosis. In conclusion, the platinum compounds
had differing toxicities based on their leaving and nonleaving ligands, and the cancer cell
lines showed different sensitivities to the same compounds.
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